Targeting Epidermal Growth Factor Receptor in triple negative breast cancer

New discoveries and practical insights for drug development

Ricardo Costa, Ami N. Shah, Cesar Santa-Maria, Marcelo R. Cruz, Devalingam Mahalingam, Benedito A. Carneiro, Young Kwang Chae, Massimo Cristofanilli, William J. Gradishar, Francis J. Giles

Research output: Contribution to journalReview article

Abstract

Triple negative breast cancer (TNBC) accounts for 10–20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.

Original languageEnglish (US)
Pages (from-to)111-119
Number of pages9
JournalCancer Treatment Reviews
Volume53
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Breast Neoplasms
Investigational Therapies
Protein-Tyrosine Kinases
Monoclonal Antibodies
Clinical Trials
Therapeutics

Keywords

  • Epidermal Growth Factor Receptor
  • mTOR
  • Targeted therapy
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer : New discoveries and practical insights for drug development. / Costa, Ricardo; Shah, Ami N.; Santa-Maria, Cesar; Cruz, Marcelo R.; Mahalingam, Devalingam; Carneiro, Benedito A.; Chae, Young Kwang; Cristofanilli, Massimo; Gradishar, William J.; Giles, Francis J.

In: Cancer Treatment Reviews, Vol. 53, 01.02.2017, p. 111-119.

Research output: Contribution to journalReview article

Costa, R, Shah, AN, Santa-Maria, C, Cruz, MR, Mahalingam, D, Carneiro, BA, Chae, YK, Cristofanilli, M, Gradishar, WJ & Giles, FJ 2017, 'Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development', Cancer Treatment Reviews, vol. 53, pp. 111-119. https://doi.org/10.1016/j.ctrv.2016.12.010
Costa, Ricardo ; Shah, Ami N. ; Santa-Maria, Cesar ; Cruz, Marcelo R. ; Mahalingam, Devalingam ; Carneiro, Benedito A. ; Chae, Young Kwang ; Cristofanilli, Massimo ; Gradishar, William J. ; Giles, Francis J. / Targeting Epidermal Growth Factor Receptor in triple negative breast cancer : New discoveries and practical insights for drug development. In: Cancer Treatment Reviews. 2017 ; Vol. 53. pp. 111-119.
@article{bd259b74e4404fa4b2db323d881b9480,
title = "Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development",
abstract = "Triple negative breast cancer (TNBC) accounts for 10–20{\%} of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.",
keywords = "Epidermal Growth Factor Receptor, mTOR, Targeted therapy, Triple negative breast cancer",
author = "Ricardo Costa and Shah, {Ami N.} and Cesar Santa-Maria and Cruz, {Marcelo R.} and Devalingam Mahalingam and Carneiro, {Benedito A.} and Chae, {Young Kwang} and Massimo Cristofanilli and Gradishar, {William J.} and Giles, {Francis J.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.ctrv.2016.12.010",
language = "English (US)",
volume = "53",
pages = "111--119",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Targeting Epidermal Growth Factor Receptor in triple negative breast cancer

T2 - New discoveries and practical insights for drug development

AU - Costa, Ricardo

AU - Shah, Ami N.

AU - Santa-Maria, Cesar

AU - Cruz, Marcelo R.

AU - Mahalingam, Devalingam

AU - Carneiro, Benedito A.

AU - Chae, Young Kwang

AU - Cristofanilli, Massimo

AU - Gradishar, William J.

AU - Giles, Francis J.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Triple negative breast cancer (TNBC) accounts for 10–20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.

AB - Triple negative breast cancer (TNBC) accounts for 10–20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.

KW - Epidermal Growth Factor Receptor

KW - mTOR

KW - Targeted therapy

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85009348128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009348128&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2016.12.010

DO - 10.1016/j.ctrv.2016.12.010

M3 - Review article

VL - 53

SP - 111

EP - 119

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -